To examine the coexpression of HER2, CD44v6, and CD36 in HER2 + BC patients with or without pCR, we combined immunofluorescence and IHC staining of FFPE tissue samples, with analysis through a digital quantitative pathology approach (see Materials and Methods). Here, CD36 is linked to breast cancer.